-Caveat Lector-
> Hemispherx Biopharma Expands Presence in Genomics ...
>
> Hemispherx Biopharma Expands Presence in Genomics Field:
> Strategic Alliance Focuses on Gulf War Syndrome
>
> PHILADELPHIA, Oct. 3 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex:
HEB;
> HEBws) announced today that it has secured a major position into the fast
> growing area of human genomics by a strategic alliance with Chronix
> Biomedical ("Chronix"), San Francisco, CA.
>
> Principals of Chronix recently testified to the Congressional Subcommittee
on
> National Security, Veterans' Affairs and International Relations on gene
> reshuffling and chronic diseases, including Gulf War Syndrome (GWS).
>
> Genomic research focuses on studying the map of the normal human genome.
> Chronix's technology is based in part on the detours or "reshuffled genes"
> the human genome map may take when confronted with viruses or other toxic
> environmental exposures.
>
> Under the strategic alliance, Hemispherx and Chronix will jointly develop
> intellectual property on new potential products for diagnosing the various
> stages of gene reshuffling, using a panel of screening tests for Chronic
> Fatigue Syndrome (CFS) and its allied maladies including GWS.
>
> Hemispherx will help develop the plasma RNA tests to market segments, and
> assist Chronix market its first product, a proprietary plasma RNA test,
which
> measures the total amount of reshuffled genes (RNA) as a research use only
> test. In addition, Hemispherx will make available to Chronix its
considerable
> CFS data bank to enable the alliance to isolate potentially unique human
gene
> sequences particular to CFS, GWS and related chronic diseases.
>
> Since the investigational drug Ampligen's(R) mode of action is on RNA in
the
> cell, the two companies plan to work together to provide a potential
> treatment rationale based on monitoring the presence of plasma RNA.
>
> Dr. William Carter, Hemispherx CEO, stated: "At Hemispherx, for a very
long
> time, we have been intrigued with the vast potential that exists in the
human
> genomic field. We are highly confident that in choosing Chronix as our
> strategic alliance partner; their core science may allow them to allocate
> human reshuffled genes to various disease categories and, in addition, the
> proprietary plasma RNA test has potential as an early warning test for
> certain disease categories."
>
> A spokesperson for Chronix, a privately held company, stated that "our
goal
> is to partner with industry leaders for various major disease segments.
The
> criteria for partner selection is to focus on companies, whose products
can
> potentially remove, control or eliminate reshuffled RNA genes. Clearly,
> Hemispherx fits that criteria in the field of CFS/GWS. Hemispherx's
expertise
> in the field, coupled with their data bank information, is expected to
> accelerate our R&D."
>
> One of the first targets of the new alliance will be GWS. It is believed
that
> approximately 50,000 veterans in the U.S. and 4,000 in allied countries
who
> served in Operation Desert Storm may have GWS/CFS. Additionally, Veterans
> Administration data indicate at least 1,300 veterans have died from cancer
> and that several thousand more have died from other diseases. Recent
> Congressional testimony suggested that a secret to GWS may lie in the
> reshuffled genes, the subject of a peer-reviewed scientific article by
> Chronix principals.
>
> Hemispherx said it would accelerate meetings with governmental officials
and
> scientific leaders to evaluate these new diagnostic and potential
therapeutic
> approaches to GWS. GWS, and the related illness CFS, often result in
extended
> hospitalizations and can drain health care resources in both military and
> civilian sectors. Dr. Carter, who previously directed multimillion-dollar
> National Institutes of Health (NIH) research grants on therapeutic
> intervention into other chronic diseases, said the civilian CFS program
would
> also go forward on an accelerated basis.
>
> Financial terms were not disclosed. The transaction will provide
Hemispherx
> with various rights concerning the diagnosis and potential treatment of
GWS,
> CFS and related viral disorders.
>
> Hemispherx Biopharma, which is based in Philadelphia, is a pharmaceutical
> company engaged in the manufacture and global clinical development of new
> drug entities in the nucleic acid (NA) class for chronic viral diseases
and
> disorders of the immune system including CFS, HIV and Hepatitis. Its
flagship
> investigational products are Ampligen(R), which is being studied to assess
> safety and efficacy in the treatment of CFS and drug-resistant HIV, and
> polyadenur, for Hepatitis B and C. Its Ampligen(R) investigational product
is
> the only investigational drug presently in advanced clinical testing
globally
> for CFS.
>
> Information contained in this news release other than historical
information,
> including the strategic alliance with Chronix and the GWS initiatives,
should
> be considered forward-looking and are subject to various risk factors and
> uncertainties. For instance, the strategies and operations of Hemispherx
> involve risks of competition, changing market conditions, changes in laws
and
> regulations affecting these industries and numerous other factors
discussed
> in this release and in the Company's filings with the Securities and
Exchange
> Commission. Accordingly, actual results may differ materially from those
in
> any forward-looking statements. Additionally, all the referenced
> investigational drugs and associated technologies of the company are
> experimental in nature and as such are not designated safe and effective
by a
> regulatory authority for general use and are legally available only to
> subjects with the referenced disorders through clinical trials. The
> forward-looking statements represent the Company's judgment as of the date
of
> this release. The Company disclaims, however, any intent or obligation to
> update these forward-looking statements. SOURCE Hemispherx Biopharma, Inc.
>
> -0- 10/03/2000
>
> /CONTACT: William A. Carter, M.D., CEO & Chairman of Hemispherx Biopharma,
> Inc., 215-988-0080, or Dianne Will, Investor Relations, 214-954-9300, or
fax,
> 214-954-9333, or Mark Kollar, Institutional Investors, 212-232-2222, or
fax,
> 212-232-3232/
>
> /Web site: http://www.hemispherx.net/ CO: Hemispherx Biopharma, Inc.;
Chronix
> Biomedical ST: Pennsylvania IN: MTC SU:
>
> Copyright 2000 PR Newswire. All rights reserved
>
>
>
<A HREF="http://www.ctrl.org/">www.ctrl.org</A>
DECLARATION & DISCLAIMER
==========
CTRL is a discussion & informational exchange list. Proselytizing propagandic
screeds are unwelcomed. Substance�not soap-boxing�please! These are
sordid matters and 'conspiracy theory'�with its many half-truths, mis-
directions and outright frauds�is used politically by different groups with
major and minor effects spread throughout the spectrum of time and thought.
That being said, CTRLgives no endorsement to the validity of posts, and
always suggests to readers; be wary of what you read. CTRL gives no
credence to Holocaust denial and nazi's need not apply.
Let us please be civil and as always, Caveat Lector.
========================================================================
Archives Available at:
http://peach.ease.lsoft.com/archives/ctrl.html
<A HREF="http://peach.ease.lsoft.com/archives/ctrl.html">Archives of
[EMAIL PROTECTED]</A>
http:[EMAIL PROTECTED]/
<A HREF="http:[EMAIL PROTECTED]/">ctrl</A>
========================================================================
To subscribe to Conspiracy Theory Research List[CTRL] send email:
SUBSCRIBE CTRL [to:] [EMAIL PROTECTED]
To UNsubscribe to Conspiracy Theory Research List[CTRL] send email:
SIGNOFF CTRL [to:] [EMAIL PROTECTED]
Om
